Across the annual disclosed results, revenue rose from KRW 179 million in 2022 to KRW 294 million in 2023 and KRW 371 million in 2024, then fell to KRW 159 million in 2025. Of the 2022 to 2025 period, 2024 was the largest year and 2025 the smallest, and 2025 revenue fell 57.2% year on year.
The operating loss was KRW 6.47 billion in 2022, KRW 6.42 billion in 2023, KRW 7.7 billion in 2024 and KRW 14.3 billion in 2025, so the loss narrowed in 2023 and widened in 2024 and 2025. The company has posted losses for four consecutive years from 2022 through 2025.
The operating margin was -8,997.2% in 2025, showing that revenue does little to offset the operating loss.
Net loss attributable to controlling shareholders was KRW 6.72 billion, KRW 1.75 billion, KRW 10.1 billion and KRW 16 billion for 2022 through 2025, and net loss including non-controlling interests was disclosed separately at KRW 6.72 billion, KRW 1.75 billion, KRW 10.1 billion and KRW 16 billion for the same years.
The debt-to-equity ratio rose from 83.0% in 2022 and 27.4% in 2023 to 70.4% in 2024 and 151.1% in 2025. At end-2025, total equity was KRW 11.9 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 17.9 billion.
Operating cash flow was -KRW 5.19 billion in 2022 and widened to -KRW 11 billion in 2025.
Quarterly, the operating loss was KRW 3.42 billion in the third quarter of 2025 and KRW 5.39 billion in the fourth quarter, narrowed to KRW 1.71 billion in the first quarter of 2026, rose to KRW 2.46 billion in the second quarter and narrowed to KRW 1.67 billion in the third quarter.
Net loss attributable to controlling shareholders was KRW 3.76 billion in the third quarter of 2025 and KRW 1.96 billion in the third quarter of 2026, and totaled KRW 12.6 billion over the most recent four quarters.
Apart from KRW 173 million in the first quarter of 2026, no quarterly revenue appears in the disclosed results. Funding has filled part of the gap: Aribio agreed in September 2026 to invest KRW 15 billion in Aribiolab's KRW 18 billion third-party rights offering. The cost items behind the widening losses can be traced in the periodic report's expense breakdown.